News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Faron and Priaxon Announce a Collaboration to Generate a New Class of AOC3/SSAO Antagonist


6/14/2010 6:10:59 AM

MUNICH & TURKU, Finland--(BUSINESS WIRE)--Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions. The goal of the collaboration is to create completely new scaffold structures to modify this interaction and the AOC3 function with orally available drugs.

Read at BioSpace.com

comments powered by Disqus
Priaxon
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES